For Research Use Only
Ipamorelin
Ipamorelin — research-grade peptide. ≥ 99% purity (HPLC), Certificate of Analysis with every batch. For laboratory research use only.
+ 1 Free 3ml BAC Water
+ 2 Free 3ml BAC Water
10 VIALS · 40% OFF
FREE- 3 Free 3ml BAC Water
- Free GLP-3 R 10mg vial
- Free Priority Shipping
Transparency
Certificate of Analysis
Every batch independently verified by third-party laboratories.
Ipamorelin COA
All Banger Labs products are independently tested by accredited third-party laboratories. Results are batch-specific and provided for research transparency only. This product is not approved for human use.
Lab Verified
Every Dose, Independently Tested
Verified by Vanguard Laboratory — always ≥99.5% purity, tested 7×. Swipe to view your selected dose.
Support
Frequently Asked Questions
Everything you need to know about this product and your order.
Research Overview Cited research summary, handling & references — tap to expand
Ipamorelin: A Research Compendium
What Ipamorelin Is
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classified as a growth hormone secretagogue — an agonist of the growth hormone secretagogue receptor (GHS-R1a, the ghrelin receptor). It belongs to the same functional family as the growth-hormone-releasing peptides (GHRPs) but is structurally minimized to five residues, several of which are non-natural or D-configured to resist proteolysis. In its discovery paper it was characterized as the first selective GH secretagogue: it released growth hormone with potency comparable to earlier GHRPs while producing minimal stimulation of ACTH, cortisol, or prolactin, a clean profile that set it apart from the broader secretagogue class.[1] That selectivity is the central reason ipamorelin became, and remains, a widely used pharmacological probe of GHS-R signaling in isolation from the corticotropic and lactotropic effects seen with less-selective compounds. Mechanistically it engages the GHS-R on pituitary somatotrophs (and on neurons in the hypothalamic circuits that govern GH release), acting through a phospholipase-C / IP3 cascade and, in parallel, by functionally opposing somatostatin tone. It is offered here strictly as a research reference standard, and the findings below are drawn entirely from preclinical and in-vitro studies.
Areas Studied in the Research Literature
Ipamorelin has a substantial preclinical literature spanning receptor pharmacology and selectivity, skeletal biology, gastrointestinal motility, somatotroph physiology, and appetite/body-weight models. Its clean selectivity profile is what makes it valuable across all of these settings, because effects can be attributed to GHS-R engagement without the confounding stress-axis activation seen with broader secretagogues. The summaries below reflect only findings reported in those published studies, each tied to its source study.
Selective GH Secretagogue
The defining characterization is selectivity: ipamorelin releases GH potently while leaving ACTH and cortisol largely unchanged. This dissociation of GH release from the stress-axis hormones distinguishes it from less-selective hexapeptide secretagogues and is the property that established it as a benchmark "clean" GHS-R agonist in the field.[1]
GHS-R / Ghrelin-Receptor Agonism
As a ghrelin-receptor agonist, ipamorelin shares the GHS-R1a pathway with the natural ligand and with related synthetic secretagogues. Comparative reviews of growth-hormone-releasing peptides and their analogs place it within the structure–activity landscape of the class, clarifying how its minimized structure preserves agonism while trimming off-target activity.[6]
Skeletal / Bone-Formation Models
In adult rats, ipamorelin counteracted a glucocorticoid-induced decrease in bone formation. This result is used to study how GHS-R–mediated GH/IGF-1 drive interacts with the skeleton, and it is one of the clearer demonstrations of an end-organ effect downstream of selective secretagogue stimulation.[2]
Gastrointestinal Motility
In a rodent model of postoperative ileus, ipamorelin functioned as an effective ghrelin mimetic on gastrointestinal motility, illustrating that GHS-R agonism produces effects in peripheral tissues and enteric circuits well beyond the pituitary somatotroph.[3]
Somatotroph Physiology
Chronic ipamorelin treatment has been used to characterize the in-vitro somatotroph response of young female rats, informing how sustained selective stimulation modulates pituitary GH-cell behavior at the receptor and cellular level.[4]
Appetite / Body-Weight Models
More recent work reports that GHS-R1a agonists, including ipamorelin, inhibited cisplatin-induced weight loss in a ferret model, extending the research line that connects this receptor to appetite regulation and anti-cachexia investigation.[5]
How It Is Studied
Across these studies ipamorelin is used as a defined pharmacological probe: applied to isolated pituitary cells, administered in rodent disease models, and compared against the natural ligand and other secretagogues to isolate GHS-R1a-specific effects. Reviews of the GHRP/secretagogue family provide the comparative framework that gives these individual experiments their interpretive context.[6]
Reconstitution, Handling & Storage (Research)
The following reflect general peptide research-handling practice described in the literature for small-peptide secretagogue reference standards; they are bench-handling notes for reference standards, not directions for use, and they apply to in-vitro and analytical work only. Exact parameters always defer to the supplier certificate of analysis and to the requirements of the specific assay being run.
Reconstitution
In published peptide-handling protocols, lyophilized Ipamorelin is brought to room temperature before opening to prevent condensation onto the hygroscopic powder, then solubilized by adding sterile or bacteriostatic water slowly down the inner vial wall. The vial is swirled gently or left to dissolve passively (never shaken) until the solution is clear; vortexing, sonication, and foaming are avoided because mechanical shear and large air–liquid interfaces can denature small peptides and drive surface adsorption losses. Diluent choice is recorded, since bacteriostatic preservatives and pH both influence how long the reconstituted reference solution remains usable on the bench.
Concentration
Working concentrations in the literature are calculated against the labeled net peptide mass rather than gross fill weight, because lyophilizates contain counter-ions, salts, and residual moisture that inflate apparent mass. The reconstitution volume is chosen so that the smallest aliquot the assay requires is still accurately pipettable, and concentration is expressed in molar terms when receptor-occupancy or potency comparisons are the experimental goal. Serial dilutions are prepared in low-binding tubes to limit peptide loss to plasticware.
Storage
Lyophilized material is reported to be most stable when kept desiccated, frozen (commonly −20 °C or colder for long-term, with −80 °C used for extended archival), and shielded from light. Once reconstituted, aqueous peptide is typically refrigerated at 2–8 °C and used within a short window; handling protocols recommend dividing the stock into single-use aliquots immediately after reconstitution so that the working material is never subjected to repeated freeze–thaw cycles, each of which can fragment or aggregate sensitive peptides and proteins.
Sterility & Records
Aseptic technique, single-use sterile needles and filters, clean-bench preparation, and logged lot, diluent, concentration, and date documentation are standard laboratory practice for reference standards. Carryover between unrelated compounds is avoided, and chain-of-custody notes accompany the vial. None of these handling notes describe, recommend, or imply administration to humans or animals; they pertain solely to in-vitro experimentation and analytical reference use by trained personnel.
Identity & Purity
Before a peptide reference standard is used in quantitative work, identity and purity are typically confirmed by analytical methods such as reversed-phase HPLC for purity and mass spectrometry for molecular-weight confirmation, with the certificate of analysis retained alongside the lot record. Verifying that the observed mass matches the theoretical mass for the intended sequence guards against truncated, oxidized, or mis-synthesized material that would confound downstream assays.
Quality-Control Notes
Visual inspection for clarity and the absence of particulates after reconstitution, confirmation that the powder fully dissolved without persistent haze, and consistency of behavior across lots are routine quality checks. Any deviation — discoloration, incomplete dissolution, or unexpected odor — is treated as a reason to set the material aside rather than risk corrupting an experiment. Where quantitative results depend on exact peptide content, an independent content assay against a characterized reference is preferred over relying on the label mass alone.
Disposal & Containment
Unused reconstituted solution, expired stock, and contaminated consumables are disposed of as laboratory waste in accordance with institutional and local regulations rather than being retained indefinitely. Work surfaces are decontaminated after use, and personal protective equipment appropriate to handling research biochemicals is worn throughout. These containment practices reinforce that the material is intended for a controlled laboratory workflow and nowhere else.
Stability & Half-Life Notes
As a small five-residue peptide, ipamorelin is characterized in the secretagogue literature by a comparatively short functional profile relative to albumin-tethered GHRH analogs; its D-amino-acid and non-natural residues confer some resistance to enzymatic breakdown but do not give it the days-long persistence of a DAC-modified construct.[1] For research storage, the dry lyophilizate is kept cold and desiccated, while reconstituted aqueous material is treated as time-limited, refrigerated, and divided into single-use aliquots to minimize freeze–thaw exposure.
Research Use Only — Not For Human Use
This material and all information presented here are provided strictly for in-vitro laboratory research and analytical reference. Ipamorelin is not a drug, dietary supplement, food, cosmetic, or medical device; it has not been evaluated or approved by any regulatory authority for the diagnosis, treatment, cure, or prevention of any condition; and it is not approved for human or veterinary use. Nothing in this overview is medical advice, a therapeutic claim, or any suggestion, instruction, or encouragement for use in or on the body of a human or animal. Every study summarized above was conducted by the cited investigators in controlled research or clinical-trial settings and is reported here only to document what exists in the peer-reviewed literature. Handling is restricted to qualified personnel operating in an appropriate research environment and in accordance with all applicable laws and institutional policies. By accessing this material the user accepts sole responsibility for its lawful, research-only use.
References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822
- Andersen NB, Malmlöf K, Johansen PB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001. PMID: 11735244
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009. PMID: 19289567
- Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histol Histopathol. 2002. PMID: 12168778
- Lu Z, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets. Physiol Behav. 2024. PMID: 39043357
- Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol. 1998. PMID: 9465289
Scientific References
Explore the published research literature on Ipamorelin. We link directly to independent, primary sources — we don't summarize or interpret findings. For research use only.
Links open external databases (pubmed.ncbi.nlm.nih.gov · clinicaltrials.gov). Banger Labs is not affiliated with these sources. For research use only — not medical advice.
Certificate of Analysis
Ipamorelin · ≥99.4% purity (HPLC)